ImmuCell Q2 Product Sales Rise 11.5% to $7.2M with 27.7% Domestic Gain
ICCC•ImmuCell reported preliminary Q2 product sales of $7.2 million, up 11.5%, driven by a 27.7% domestic increase despite a 38.9% drop in international sales. For the first half of 2026, total sales reached $17.5 million, a 20.9% rise led by 25.1% growth in Tri-Shield® and 10.9% growth in Dual-Force®.
1. Q2 Sales Overview
ImmuCell posted $7.2 million in preliminary product sales for Q2 2026, marking an 11.5% increase over Q2 2025. Domestic revenues surged 27.7% to $6.2 million, while international sales declined 38.9% to $1.0 million, reflecting strong U.S. demand and a challenging year-over-year distributor comparison.
2. First-Half 2026 Results
For the six months ended June 30, 2026, total product sales reached $17.5 million, up 20.9% from $14.5 million a year earlier. Domestic sales grew 32.5% to $16.0 million, and product lines saw Tri-Shield® sales rise 25.1% to $12.8 million and Dual-Force® sales increase 10.9% to $4.8 million.
3. Commercial Strategy and Product Performance
Management focused commercial efforts on price-sensitive, year-round dairy customers, fueling a 23.8% increase in Dual-Force® demand and an 8.3% lift in Tri-Shield® orders. Expansion of the commercial team has contributed to stronger customer acquisitions and improved product availability in core U.S. markets.
4. Investor Conference Call
ImmuCell will host a conference call on August 14, 2026 at 9:00 AM ET to discuss full Q2 results, revenue drivers and strategic initiatives. Interested parties can join the call live to review detailed financial metrics and management’s outlook.
